These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 18384998)

  • 1. The efficacy and safety of ceftobiprole in the treatment of complicated skin and skin structure infections: evidence from 2 clinical trials.
    Deresinski SC
    Diagn Microbiol Infect Dis; 2008 May; 61(1):103-9. PubMed ID: 18384998
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical profile of ceftobiprole, a novel beta-lactam antibiotic.
    Noel GJ
    Clin Microbiol Infect; 2007 Jun; 13 Suppl 2():25-9. PubMed ID: 17488373
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ceftobiprole: an extended-spectrum anti-methicillin-resistant Staphylococcus aureus cephalosporin.
    Anderson SD; Gums JG
    Ann Pharmacother; 2008 Jun; 42(6):806-16. PubMed ID: 18477729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ceftobiprole: a novel cephalosporin with activity against Gram-positive and Gram-negative pathogens, including methicillin-resistant Staphylococcus aureus (MRSA).
    Barbour A; Schmidt S; Rand KH; Derendorf H
    Int J Antimicrob Agents; 2009 Jul; 34(1):1-7. PubMed ID: 19261449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections.
    Noel GJ; Bush K; Bagchi P; Ianus J; Strauss RS
    Clin Infect Dis; 2008 Mar; 46(5):647-55. PubMed ID: 18225981
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antimicrobial activity of ceftobiprole, a novel anti-methicillin-resistant Staphylococcus aureus cephalosporin, tested against contemporary pathogens: results from the SENTRY Antimicrobial Surveillance Program (2005-2006).
    Fritsche TR; Sader HS; Jones RN
    Diagn Microbiol Infect Dis; 2008 May; 61(1):86-95. PubMed ID: 18385000
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ceftobiprole: a new cephalosporin for the treatment of skin and skin structure infections.
    Schirmer PL; Deresinski SC
    Expert Rev Anti Infect Ther; 2009 Sep; 7(7):777-91. PubMed ID: 19735220
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ceftobiprole: a new broad spectrum cephalosporin.
    El Solh A
    Expert Opin Pharmacother; 2009 Jul; 10(10):1675-86. PubMed ID: 19527192
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ceftobiprole: first cephalosporin with activity against methicillin-resistant Staphylococcus aureus.
    Vidaillac C; Rybak MJ
    Pharmacotherapy; 2009 May; 29(5):511-25. PubMed ID: 19397461
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Results of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by gram-positive bacteria.
    Noel GJ; Strauss RS; Amsler K; Heep M; Pypstra R; Solomkin JS
    Antimicrob Agents Chemother; 2008 Jan; 52(1):37-44. PubMed ID: 17954698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ceftaroline fosamil: a novel broad-spectrum cephalosporin with expanded anti-Gram-positive activity.
    Biek D; Critchley IA; Riccobene TA; Thye DA
    J Antimicrob Chemother; 2010 Nov; 65 Suppl 4():iv9-16. PubMed ID: 21115457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic and pharmacodynamic profile of ceftobiprole.
    Lodise TP; Patel N; Renaud-Mutart A; Gorodecky E; Fritsche TR; Jones RN
    Diagn Microbiol Infect Dis; 2008 May; 61(1):96-102. PubMed ID: 18384996
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ceftobiprole - a case study.
    Page MG
    Expert Opin Drug Discov; 2007 Jan; 2(1):115-29. PubMed ID: 23496040
    [TBL] [Abstract][Full Text] [Related]  

  • 14. What's new and not so new on the antimicrobial horizon?
    French GL
    Clin Microbiol Infect; 2008 Dec; 14 Suppl 6():19-29. PubMed ID: 19040463
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ceftobiprole: a review of a broad-spectrum and anti-MRSA cephalosporin.
    Zhanel GG; Lam A; Schweizer F; Thomson K; Walkty A; Rubinstein E; Gin AS; Hoban DJ; Noreddin AM; Karlowsky JA
    Am J Clin Dermatol; 2008; 9(4):245-54. PubMed ID: 18572975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ceftaroline for complicated skin and skin-structure infections.
    Nannini EC; Stryjewski ME; Corey GR
    Expert Opin Pharmacother; 2010 May; 11(7):1197-206. PubMed ID: 20402556
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In-vitro profile of a new beta-lactam, ceftobiprole, with activity against methicillin-resistant Staphylococcus aureus.
    Jones ME
    Clin Microbiol Infect; 2007 Jun; 13 Suppl 2():17-24. PubMed ID: 17488372
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cefdinir vs. cephalexin for mild to moderate uncomplicated skin and skin structure infections in adolescents and adults.
    Giordano PA; Elston D; Akinlade BK; Weber K; Notario GF; Busman TA; Cifaldi M; Nilius AM
    Curr Med Res Opin; 2006 Dec; 22(12):2419-28. PubMed ID: 17257456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ceftaroline fosamil: a novel broad-spectrum cephalosporin with activity against methicillin-resistant Staphylococcus aureus.
    Jorgenson MR; DePestel DD; Carver PL
    Ann Pharmacother; 2011 Nov; 45(11):1384-98. PubMed ID: 22009993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antimicrobial management of complicated skin and skin structure infections in the era of emerging resistance.
    Lee SY; Kuti JL; Nicolau DP
    Surg Infect (Larchmt); 2005; 6(3):283-95. PubMed ID: 16201938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.